Bret, P, Bret, MC, Queuille, E.
Prescribing patterns of antipsychotics in 13 French psychiatric hospitals [in French]. L'Encephale
2009; 35: 129–38.
Koranek, AM, Smith, TL, Mican, LM, Rascati, KL. Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility. Schizophr Res
2012; 137: 137–40.
Park, SC, Lee, MS, Kang, SG, Lee, SH. Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review and assessment service – national patient sample. J Korean Med Sci
2014; 29: 719–28.
Jauhar, S, Guloksuz, S, Andlauer, O, Lydall, G, Marques, JG, Mendonca, L, et al. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?
2012; 12: 27.
Cheng, F, Jones, PB. Drug treatments for schizophrenia: pragmatism in trial design shows lack of progress in drug design. Epidemiol Psychiatr Sci
2013; 22: 223–33.
Underwood, BR. Dominance of second-generation antipsychotics – time for reflection?
2007; 31: 233.
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.
Lewis, S, Lieberman, J.
CATIE and CUtLASS: can we handle the truth?
Br J Psychiatry
2008; 192: 161–3.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Peluso, MJ, Lewis, SW, Barnes, TR, Jones, PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry
2012; 200: 387–92.
National Institute for Health and Care Excellence. Psychosis and Schizophrenia: Treatment and Management
. NICE, 2014.
Farde, L, Nordstrom, AL, Wiesel, FA, Pauli, S, Halldin, C, Sedvall, G.
Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry
1992; 49: 538–44.
Owens, DC. Meet the relatives: a reintroduction to the clinical pharmacology of ‘typical’ antipsychotics (Part 2). Adv Psychiatr Treat
2012; 18: 337–50.
Karthik, MS, Warikoo, N, Chakrabarti, S, Grover, S, Kulhara, P.
Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications. Indian J Psychol Med
2014; 36: 288–93.